Methyl 2-Amino-4-Thiazoleformate

How Is Methyl 2-Aminothiazole-4-carboxylate Processed into the Universal Cephalosporin Side Chain ATMA?

During the synthesis of the universal 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid (ATMA) side chain, which is subsequently activated as an active ester or acid chloride for acylation of the 7-aminocephalosporanic acid (7-ACA) nucleus, precise stoichiometric control over methyl 2-aminothiazole-4-carboxylate relative to methoxyamine hydrochloride is exercised at a molar ratio of 1:1.08 to 1:1.15 within a 1000 L glass-lined reactor equipped with a retreat-curve impeller and a baffled jacket capable of maintaining an internal jacket brine temperature of -10°C. The reactor is charged with the ester, methanol, and water, then methoxyamine hydrochloride is added portion-wise over 90 minutes while the pH of the slurry is continuously adjusted to 4.8–5.2 using 30% w/w sodium carbonate solution; any pH excursion above 5.5 promotes a base-catalyzed oxime isomerization pathway that shifts the geometric composition toward the pharmacologically inactive E-isomer. The mass temperature is held at 0–5°C not merely for selectivity, but because the exothermic imine formation and subsequent methyl oxime generation exhibit a combined adiabatic temperature rise of 18°C per mole of ester converted—exceeding the thermal half-life threshold of the Z-oxime ester at 25°C, where 3.2% E-isomer is generated within 2 hours as determined by a forced degradation study conducted on a 50 L pilot batch. Process analytical technology (PAT) deployed on the manufacturing line includes an inline Attenuated Total Reflectance (ATR) Fourier Transform Infrared probe, configured to track the disappearance of the ester carbonyl stretch at 1715 cm⁻¹ and the appearance of the methoxyimino absorbance at 1040 cm⁻¹; the batch is deemed complete when the residual ester peak area integrates to less than 0.3% of the initial value. The reaction mass is then subjected to alkaline hydrolysis with 2.5 M sodium hydroxide at 10–15°C, converting the ester to the corresponding sodium 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetate without racemization or oxime cleavage, followed by acidification to isoelectric point 5.2–5.4 using 36% hydrochloric acid, which precipitates ATMA monohydrate. Drying is conducted in a conical vacuum dryer with a rotating helical ribbon agitator at a jacket temperature of 45°C under 50 mbar absolute pressure, targeting a loss-on-drying endpoint of 0.15–0.25%. The dried ATMA lot must comply with the residual solvent limits prescribed in ICH Q3C tables for Class 2 solvents (methanol 3000 ppm, methylene chloride 600 ppm, tetrahydrofuran 720 ppm) and with absence of mutagenic oxime ether impurities as per ICH M7 (TTC 1.5 μg/day). The Z/E isomer ratio is quantified by a reversed-phase HPLC method employing a C18 column ( 250 mm × 4.6 mm, 5 μm) and an isocratic mobile phase of 0.1% phosphoric acid/methanol (65:35 v/v) at 1.0 mL/min, with UV detection at 254 nm; the specification requires Z-isomer ≥ 99.5% and E-isomer ≤ 0.5%. The terminal products derived from this intermediate stream include the sterile, lyophilized sodium salts of ceftriaxone, cefotaxime, and ceftizoxime, which are subsequently filled into Type II glass vials under Grade A laminar flow and terminally sterilized by gamma irradiation at a minimum absorbed dose of 25 kGy, as validated in accordance with ISO 11137-2:2013. The table below documents the effect of reaction temperature on the isomeric distribution of the protected oxime ester intermediate, obtained from a design-of-experiments study on a 100 kg scale campaign.

In the manufacture of orally administered cephalosporins such as cefdinir and cefixime, the amino and ester functions of methyl 2-aminothiazole-4-carboxylate are sequentially activated to produce reactive hydrochloride salts or silylated intermediates that suppress premature N-acylation when the thiazole ring is condensed with advanced diphenylmethyl or p-methoxybenzyl protected 7-amino-3-vinyl-3-cephem-4-carboxylic acid blocks. The ester is first protected at the 2-amino position with di-tert-butyl dicarbonate (Boc₂O) at a molar ratio of substrate to anhydride of 1:1.05 in dichloromethane at 20–25°C in the presence of 4-dimethylaminopyridine (0.05 eq), a step that proceeds to >98% conversion within 3 h and must be followed by an aqueous citric acid wash (10% w/w) to remove residual amine catalyst, which otherwise promotes Boc migration to the ester oxygen and results in an N,O-bis-Boc impurity that co-crystallizes with the target N-Boc methyl ester and reduces yield of the subsequent enzymatic ester cleavage. The N-Boc intermediate is then subjected to ester hydrolysis using an immobilized Candida antarctica lipase B formulation (CALB, 20,000 PLU/g) in a biphasic mixture of phosphate buffer (pH 7.0, 0.1 M) and methyl tert-butyl ether at 30°C under gentle overhead stirring in a 500 L stainless steel reactor with a bottom discharge valve; the enzymatic step avoids the racemization and β-lactam ring-opening side reactions that accompany saponification with alkali hydroxide. The key regulatory compliance thresholds applied to the resultant N-Boc-2-aminothiazole-4-carboxylic acid and its activated p-nitrophenyl ester include a residual Boc impurity content of ≤ 0.10% by area normalization in the HPLC purity assay, justified under USP ⟨1462⟩ for actual impurity control, and an individual unspecified impurity limit of 0.10% as mandated by ICH Q3A(R2) for drug substances (daily dose ≤ 2 g). The terminal dosage forms from this processing stream are cefdinir capsules (300 mg) and cefixime for oral suspension (100 mg/5 mL), which must demonstrate bioequivalence to reference listed drugs per ICH E6(R3) and dissolution compliance using USP Apparatus 2 at 50 rpm in 900 mL of pH 1.2 dissolution medium.

When the Ester Route Replaces Carboxylic Acid in Ceftiofur Side Chain Synthesis: Veterinary Drug Requirements

Veterinary cephalosporin hydrochloride salts demand stringent control of residual methanol and methylating agent by-products that originate from the methyl ester moiety of methyl 2-aminothiazole-4-carboxylate when it is employed in the construction of the (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl side chain intended for ceftiofur hydrochloride and cefquinome sulfate. The ester is directly condensed with the free amine of 7-amino-3-[(furanylcarbonyl)thiomethyl]cepham-4-carboxylic acid (ceftiofur nucleus) in N,N-dimethylacetamide at -20°C utilizing dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBt) at a molar ratio of ester to 7-amino nucleus of 1:1.01—the near-stoichiometric quantity of the activated ester component is forced by the need to minimize residual DCC-derived dicyclohexylurea, a contaminant that, at levels above 0.3% w/w in the isolated product, induces delayed hypersensitivity reactions in swine and cattle. The coupling is conducted in a 3000 L hastelloy reactor with a triple-flight ribbon agitator rotating at 45 rpm, and the reaction mass is quenched into 15 volumes of purified water pre-chilled to 2°C, causing the ceftiofur side chain-ester adduct to precipitate as a fine, filterable crystalline solid. Global veterinary regulatory compliance is aligned with VICH GL10 (impurities in new veterinary drug substances) and VICH GL11 (impurities in new veterinary medicinal products), establishing a reporting threshold of 0.05%, an identification threshold of 0.10%, and a qualification threshold of 0.15% for the process-related 2-aminothiazole-derived impurities that are monitored by gradient HPLC with a phenyl-hexyl stationary phase and detection at 260 nm. Residual 2-aminothiazole-4-carboxylic acid methyl ester in the ceftiofur side chain intermediate must be controlled to ≤ 0.05% as a potential genotoxic impurity, with an acceptable intake of 1.5 μg/day for a 500 kg bovine, translating to a concentration limit of 3.0 ppm in the final sterile injectable suspension. The terminal veterinary products are ceftiofur hydrochloride sterile suspension ( 50 mg/mL ) supplied in 100 mL multi-dose vials and ceftiofur sodium powder for intramammary infusion in lactating dairy cows, with a milk withdrawal period of 72 h established from tissue residue depletion studies conducted under GLP principles.

Solid-phase parallel synthesis platforms exploit the orthogonal reactivity of methyl 2-aminothiazole-4-carboxylate as a bifunctional building block wherein the primary amine engages in reductive amination or peptide coupling while the methyl ester remains intact, later serving as a traceless linker attachment point upon saponification or direct aminolysis with terminal amines during the cleavage step from a Wang or trityl resin. In a typical DNA-encoded library (DEL) synthesis campaign executed on a fully automated multichannel synthesizer equipped with 24 parallel reaction vessels and an integrated solid-phase extraction module, the building block is pre-activated as its pentafluorophenyl ester using N,N’-diisopropylcarbodiimide and pentafluorophenol in dry dimethylformamide at a concentration of 0.25 M and coupled to the resin-bound amine at a 5-fold molar excess relative to the resin loading capacity of 0.8 mmol/g; the coupling efficiency is assessed by the Kaiser test (ninhydrin) at 120°C for 5 min, a semi-quantitative colorimetric method that provides a limit of detection of 5 μmol/g residual amine and triggers a double-coupling cycle if a positive blue coloration persists. Following the assembly cycle, the methyl ester is converted to a hydrazide using 3% hydrazine in methanol at 40°C for 12 h, then cyclized with carbon disulfide and potassium hydroxide to furnish a 1,3,4-thiadiazole-2-thiol fused to the original thiazole scaffold—a privileged heterocyclic motif in kinase inhibitor discovery. While no statutory pharmacopoeial monograph applies to compound libraries, internal quality specifications require that the average purity of single library members, as determined by LC-MS (ESI+) with evaporative light scattering detection, exceeds 85% and that palladium content from earlier cross-coupling steps be ≤ 50 ppm, measured by inductively coupled plasma optical emission spectrometry (ICP-OES) per USP ⟨233⟩, to avoid false-positive biological screening results. The terminal deliverables from this workflow are 384-well microtiter plates containing 50 μL aliquots of dry-film compound libraries, each member uniquely tagged with a double-stranded DNA barcode, destined for high-throughput screening against recombinant bacterial enoyl-ACP reductase enzyme targets.

The Ligand Stream: Manufacturing Chiral Thiazole-Phosphine Ligands for Palladium-Catalyzed Cross-Couplings

Industrial-scale batches of thiazole-phosphine ligands derived from methyl 2-aminothiazole-4-carboxylate serve as critical phosphine donors in palladium-catalyzed carbon-nitrogen and carbon-carbon bond-forming reactions used to manufacture specialty electronic intermediates and active pharmaceutical ingredients requiring sterically demanding biaryl systems. The manufacturing sequence begins with the protection of the aromatic amine as its trimethylsilyl (TMS) derivative using hexamethyldisilazane (2.2 eq) and catalytic saccharin (0.05 eq) at 80°C in toluene in a 100 L glass-lined reactor with a packed column reflux condenser, followed by dropwise addition of a 1.0 M solution of chlorodiphenylphosphine in anhydrous tetrahydrofuran at -78°C under a defined argon blanket (99.999% purity, oxygen residual ≤ 0.5 ppm) maintained by a 2 kW Cryocool immersion probe. The ligand formation proceeds via lithium-halogen exchange with n-butyllithium (1.05 eq, 2.5 M in hexane) on the 4-position of the thiazole ring after directed ortho-metallation facilitated by the carbomethoxy group; the metallated species is quenched with the chlorophosphine at a rate not exceeding 0.5 mL/min to suppress the formation of diphenylphosphine oxide, a trivalent phosphorus impurity that coordinates palladium strongly and deactivates the catalytic cycle. The reaction mixture is warmed to -20°C over 2 h and hydrolyzed with deoxygenated 10% sodium chloride solution, and the pentane-extracted ligand is purified by fractional distillation under a vacuum of 0.01 mbar using a wiped-film evaporator with an evaporator surface temperature of 180°C, yielding the free-flowing, air-sensitive ligand in 76–82% isolated yield. All handling of the neat ligand is conducted inside a glovebox maintaining an oxygen level < 1 ppm and a moisture level < 0.5 ppm; the compound is packaged in septum-sealed amber glass vials under argon and shipped with an integrated oxygen absorber packet. The elemental impurity specification for the ligand, aligned with ICH Q3D for therapeutic products manufactured with the derived catalyst, sets the palladium concentration at ≤ 10 ppm, iron ≤ 200 ppm, and nickel ≤ 25 ppm as measured by ICP-MS following microwave-assisted acid digestion, with the method detection limit validated to 0.1 ppm for Pd. The table below summarizes the residual metaloid thresholds and corresponding batch analysis data for the ligand lot manufactured in a 25 kg campaign, benchmarked against the oral and parenteral PDEs of the target API product stream.

2-Aminothiazole-derived fluorescent whitening agents (FWAs) for polyester fibers require a carboxylate anchoring group to provide substantivity during the thermosol pad-dry process, and methyl 2-aminothiazole-4-carboxylate serves as a direct heterocyclic platform for constructing bis(benzoxazolyl)stilbene analogs where the thiazole ring replaces one of the oxazole moieties to shift the emission maximum from 436 nm into the violet-blue region of 420–430 nm, creating a desirable bluish-white optical contribution on polyethylene terephthalate fabric post-thermofixation at 190°C for 90 s. The building block is condensed with salicylaldehyde in ethanol under reflux in the presence of boric acid catalyst at a molar ratio of 1:1.02, forming a Schiff base that is cyclodehydrated to the benzothiazole-imine intermediate using phosphorus oxychloride in chlorobenzene at 105°C over 5 h in a 500 L enamel-lined steel reactor equipped with a scrubbing system for hydrogen chloride off-gas. The resulting heterocyclic acid is isolated by drowning into ice water, filtered, and vacuum-dried at 80°C for 16 h. Compliance for textile auxiliaries is demonstrated against the ecological criteria of OEKO-TEX Standard 100, appendix 4 for extractable heavy metals (antimony ≤ 30 mg/kg, arsenic ≤ 1.0 mg/kg), and against the SVHC Candidate List under REACH (EC No. 1907/2006) for substances of very high concern; the compound must contain less than 0.1% w/w of free 2-aminothiazole, a structural alert for sensitization per the KeratinoSensTM assay, to qualify for use in apparel-grade optically brightened polyester staple fiber. The terminal consumer product is a 20% active liquid dispersion of the benzoxazolethiazole FWA, designated C.I. Fluorescent Brightener 351, applied at 0.02–0.05% on weight of fiber in a pad trough prior to stenter framing.